0001498382 false 0001498382 2022-12-05 2022-12-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares















Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2022





(Exact name of Registrant as Specified in Its Charter)




Nevada   001-37823   99-0360497

(State or other jurisdiction
of incorporation)

File Number)

(IRS Employer
Identification No.)


9920 Pacific Heights Blvd, Suite 150

San Diego, CA 92121

    (Address of principal executive offices)    


Registrant’s Telephone Number, Including Area Code: (858) 350-4364



(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4©)


Securities registered pursuant to Section 12(b) of the Act:


Title of each class  

Trading Symbol(s)

  Name of each exchange on which registered
Common Stock   KTRA  

The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 2.02Results of Operations and Financial Condition.


As previously disclosed, Kintara Therapeutics, Inc. (the “Company”) paused its REM-001 program in Cutaneous Metastatic Breast Cancer to conserve cash which will be used to support the funding of the Company’s ongoing international registrational study for VAL-083 in glioblastoma. The Company anticipates announcing topline data around the end of calendar year 2023. By pausing the REM-001 program, the Company expects to save approximately $3.0 million through calendar year 2023. Additionally, the Company recently reviewed and reduced expenses in other areas. As a result, and based on current operating plans, the Company expects that its cash and cash equivalents as of September 30, 2022 are sufficient to finance its anticipated cash requirements into the third quarter of calendar year 2023 and reduced cash required to enter calendar year 2024 to approximately $3.0 million. 


Item 7.01Regulation FD Disclosure.


See “Item 2.02 Results of Operations and Financial Condition” above.


The information in this Current Report on Form 8-K under Items 2.02 and 7.01 is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by a specific reference in such filing.


Item 8.01 Other Events.


The Company has prepared presentation materials (the “Investor Presentation”) in connection with management presentations to describe its business. A copy of the Investor Presentation has been posted to the Company’s website and is attached as Exhibit 99.1 hereto.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


Exhibit No.   Description




Investor Presentation


104   Cover Page Interactive Data File (embedded within the Inline XBRL document)






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: December 5, 2022 By: /s/ Scott Praill
  Name: Scott Praill
  Title: Chief Financial Officer